The Design of mRNA

UTR design：the untranslated region (UTR) is located at 5' or 3' end of the mature mRNA molecule. The regulatory elements in UTR can enhance the stability of mRNA, prolong its half-life, and improve the efficiency of translation.

Cap design：the cap structure at 5' end of mRNA can enhance the stability of mRNA and efficiently increase protein expression.

Poly(A) design：the poly(A) structure at 3' end of mRNA can effectively enhance the stability of mRNA and improve the efficiency of translation.

Nucleotide modification：the modified nucleotides can efficiently decrease the innate immune response of human body to mRNA molecule, and enhance the stability of mRNA and efficiency of translation.

Codon modification: the mRNA with common synonymous codons instead of rarer codons has higher protein expression level.

The Synthesis of mRNA

In terms of producing mRNA, Rhegen Bio has advanced synthetic and pharmaceutical technology.

Synthetic technology：the conventional method for synthesizing mRNA is relatively complicated, and the quality standard is difficult to control. Rhegen has advanced technology for mRNA synthesis and optimized process operation, which can significantly reduce the cost of mRNA production.

Pharmaceutical technology：The mRNA medicines with optimized pharmaceutical preparation could have better therapeutic effect for different diseases. Rhegen has accumulated much experience and held numbers of core patents in this technical field.

The Delivery of mRNA

The natural mRNA with poor stability is easy to be degraded by nucleases in vivo, so an appropriate delivery system is necessary to enable mRNA expression in the body. Through independent basic research, Rhegen has developed a variety of mRNA delivery technologies, which allows mRNA efficient expression in specific organs or tissues.